362 related articles for article (PubMed ID: 32182692)
1. Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology.
Dabrowska M; Ciolak A; Kozlowska E; Fiszer A; Olejniczak M
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182692
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington's Disease.
Alkanli SS; Alkanli N; Ay A; Albeniz I
Mol Neurobiol; 2023 Mar; 60(3):1486-1498. PubMed ID: 36482283
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy for Huntington's Disease Using Targeted Endonucleases.
Dabrowska M; Olejniczak M
Methods Mol Biol; 2020; 2056():269-284. PubMed ID: 31586354
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal instability during neurogenesis in Huntington's disease.
Ruzo A; Croft GF; Metzger JJ; Galgoczi S; Gerber LJ; Pellegrini C; Wang H; Fenner M; Tse S; Marks A; Nchako C; Brivanlou AH
Development; 2018 Jan; 145(2):. PubMed ID: 29378824
[TBL] [Abstract][Full Text] [Related]
5. Generation of Rhesus Macaque Embryos with Expanded CAG Trinucleotide Repeats in the
Ryu J; Statz JP; Chan W; Oyama K; Custer M; Wienisch M; Chen R; Hanna CB; Hennebold JD
Cells; 2024 May; 13(10):. PubMed ID: 38786052
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Based Genome-Editing Tools for Huntington's Disease Research and Therapy.
Qin Y; Li S; Li XJ; Yang S
Neurosci Bull; 2022 Nov; 38(11):1397-1408. PubMed ID: 35608753
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease.
Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337
[TBL] [Abstract][Full Text] [Related]
8. Introducing an expanded CAG tract into the huntingtin gene causes a wide spectrum of ultrastructural defects in cultured human cells.
Morozova KN; Suldina LA; Malankhanova TB; Grigor'eva EV; Zakian SM; Kiseleva E; Malakhova AA
PLoS One; 2018; 13(10):e0204735. PubMed ID: 30332437
[TBL] [Abstract][Full Text] [Related]
9. Introducing an Expanded Trinucleotide Repeat Tract into the Human Genome for Huntington's Disease Modeling In Vitro.
Malankhanova T; Sorokin M; Medvedev S; Zakian S; Malakhova A
Curr Protoc Hum Genet; 2020 Jun; 106(1):e100. PubMed ID: 32469433
[TBL] [Abstract][Full Text] [Related]
10. CRISPR takes on Huntington's disease.
Eisenstein M
Nature; 2018 May; 557(7707):S42-S43. PubMed ID: 29844549
[No Abstract] [Full Text] [Related]
11. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.
Shin JW; Kim KH; Chao MJ; Atwal RS; Gillis T; MacDonald ME; Gusella JF; Lee JM
Hum Mol Genet; 2016 Oct; 25(20):4566-4576. PubMed ID: 28172889
[TBL] [Abstract][Full Text] [Related]
12. Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts.
Ciesiolka A; Stroynowska-Czerwinska A; Joachimiak P; Ciolak A; Kozlowska E; Michalak M; Dabrowska M; Olejniczak M; Raczynska KD; Zielinska D; Wozna-Wysocka M; Krzyzosiak WJ; Fiszer A
Cell Mol Life Sci; 2021 Feb; 78(4):1577-1596. PubMed ID: 32696070
[TBL] [Abstract][Full Text] [Related]
13. Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington's disease.
Yan S; Zheng X; Lin Y; Li C; Liu Z; Li J; Tu Z; Zhao Y; Huang C; Chen Y; Li J; Song X; Han B; Wang W; Liang W; Lai L; Li XJ; Li S
Nat Biomed Eng; 2023 May; 7(5):629-646. PubMed ID: 36797418
[TBL] [Abstract][Full Text] [Related]
14. Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells.
Xu X; Tay Y; Sim B; Yoon SI; Huang Y; Ooi J; Utami KH; Ziaei A; Ng B; Radulescu C; Low D; Ng AYJ; Loh M; Venkatesh B; Ginhoux F; Augustine GJ; Pouladi MA
Stem Cell Reports; 2017 Mar; 8(3):619-633. PubMed ID: 28238795
[TBL] [Abstract][Full Text] [Related]
15. Huntington's Disease: Relationship Between Phenotype and Genotype.
Sun YM; Zhang YB; Wu ZY
Mol Neurobiol; 2017 Jan; 54(1):342-348. PubMed ID: 26742514
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo.
Monteys AM; Ebanks SA; Keiser MS; Davidson BL
Mol Ther; 2017 Jan; 25(1):12-23. PubMed ID: 28129107
[TBL] [Abstract][Full Text] [Related]
17. Targeting N-Terminal Huntingtin with a Dual-sgRNA Strategy by CRISPR/Cas9.
Wu J; Tang Y; Zhang CL
Biomed Res Int; 2019; 2019():1039623. PubMed ID: 31828084
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
19. Promotion of somatic CAG repeat expansion by Fan1 knock-out in Huntington's disease knock-in mice is blocked by Mlh1 knock-out.
Loupe JM; Pinto RM; Kim KH; Gillis T; Mysore JS; Andrew MA; Kovalenko M; Murtha R; Seong I; Gusella JF; Kwak S; Howland D; Lee R; Lee JM; Wheeler VC; MacDonald ME
Hum Mol Genet; 2020 Nov; 29(18):3044-3053. PubMed ID: 32876667
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9-Mediated Genome Editing for Huntington's Disease.
Vachey G; Déglon N
Methods Mol Biol; 2018; 1780():463-481. PubMed ID: 29856031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
